

## Eurofins Biomnis, driving innovation in medical biology

Established in 1897 by Marcel Mérieux, Eurofins Biomnis is the European leader in specialised medical biology. A leading player on the strength of constant technological innovation and investment, the laboratory's mission is to ensure that all patients anywhere in the country have access to state-of-the-art techniques for diagnosis and for therapeutic monitoring and adjustment. With more than 2,500 tests, Eurofins Biomnis covers a wide variety of fields such as oncology, prenatal biology, and chromosome/molecular genetics. The laboratory supports all the actors in the healthcare chain and actively contributes to creating the medicine of tomorrow.

### Clinical pathology at the service of the medicine of tomorrow

Diagnose, predict the response to treatment, monitor patients; the range of biological tests offered by Eurofins Biomnis is extremely broad with 2,500 individual tests. In order to respond more specifically to medical needs, every year the laboratory extends its catalogue of new innovative, specialised or complex tests. With its team of highly qualified experts and sophisticated equipment it is able to perform more than 32,000 analyses per day, which local or hospital laboratories are not able to carry out, with 90% of the results available the next day.

Two key factors are embedded in the DNA of Eurofins Biomnis: firstly the industrialisation of processes to ensure the shortest turnaround times with the best methods under the optimum economic conditions, and secondly innovation to create the clinical pathology of tomorrow and added value for prescribers and patients.

### Innovation and high quality care for all



François CORNU, CEO of  
Eurofins Biomnis

Innovation is the driver of Eurofins Biomnis' growth. A third of investment is channelled into the development of even more tests with very high medical added value. In this regard, Eurofins Biomnis benefits, in addition to its internal resources, from the know-how of Eurofins Clinical Diagnostics, which has outstanding, internationally recognised expertise with a portfolio of 150,000 analytical methods. Eurofins Biomnis systematically surveys health professionals to learn about the new medical needs of prescribers.

Equity of healthcare is also an important value for Eurofins Biomnis. The laboratory makes every effort to ensure that anyone living in France and elsewhere in Europe, even in the most remote areas, has access to the most innovative tests for optimum healthcare. This commitment is expressed in at least three ways: perfectly coordinated logistics, the development of efficient computer systems and efforts to ensure the reimbursability of tests. *"On the French national market in particular, our efficient logistics make it possible to collect samples across the country under secure conditions and complete the tests as soon as possible. We assure the traceability of the samples and the complete confidentiality of transmission of the results. Finally, to promote the reimbursability and access to new innovative tests, we continuously liaise with the public authorities, which are solely in a position to determine eligibility for reimbursement by the National Fund for Health Insurance,"* explains François Cornu, CEO of Eurofins Biomnis.

## 2,500 tests covering all clinical pathology specialties

With its wide range of expertise, Eurofins Biomnis can offer tests that cover more than thirty specialisms such as oncology, prenatal medicine and preventive biology as well as in infectiology, toxicology, immunity, metabolism or mental health. In 2019, two innovative tests were introduced: [a diagnostic tool for hereditary infertility in males](#) and [the ABCB1 test, to predict the response to antidepressants](#).

In **biological oncology**, important discoveries in basic research and the introduction of new analytical methods have enabled the laboratory to make great strides towards truly personalised medicine. Among other things, Eurofins Biomnis offers [a pre-therapeutic screening test for 5-fluorouracil toxicity \(5-FU\)](#), an anticancer drug used in almost 60% of oncological chemotherapy regimens.

In **prenatal medicine**, Eurofins Biomnis is deeply involved in the field of medically assisted procreation as well as in prenatal screening and diagnosis, with tests for pregnant women and the foetus. The laboratory offers [a non-invasive prenatal screening test \(DPNI\) for foetal trisomy](#) based on a simple blood test to all pregnant women whose risk level by serum markers is between 1/1000 and 1/51.

Finally, in **preventive clinical pathology**, the laboratory offers personalised support for each individual to prevent signs of ageing related to personal medical history, lifestyle and environment. It has developed the [Juvenalis® panel of preventive biological analyses](#) to evaluate metabolic, hormonal, micronutritional or digestive profiles in order to prevent, among other things, the occurrence of diseases or to identify the possible causes of an illness.

### Facts and figures

More than **120 years** of accumulated experience

**2,500 tests** available

**32,000 analyses** performed per day

**662 employees** including **42 clinical pathologists** and

a team of just under **300 technicians and technical staff**

**5,000 local partners** in France (clinical pathology laboratories or hospitals)

international partners in **40 countries worldwide**

Net sales in 2017: **EUR 148 million**

**Two specialist sites:**

**Ivry-sur-Seine (94)** for high volume analyses with short turnaround times

**Lyon (69)** for highly specialised analyses especially in genetics, oncology and infectiology

### Press contact

Aurélia Meunier, Gaëlle Ryouq

[biomnis@wellcom.fr](mailto:biomnis@wellcom.fr)

(+33) 01 46 34 60 60

### About Eurofins Biomnis

European leader in the sector of specialised clinical pathology, Eurofins Biomnis carries out over 32,000 analyses per day from a range of over 2,500 available tests, including specialised tests for which the company has the appropriate authorisations. Founded in 1897 by Marcel Mérieux, Eurofins Biomnis is the leader in specialised clinical pathology in France. It has maintained this leading position through continuous technological innovation and investment, particularly in areas such as female biology, oncology and personalised medicine, as well as chromosomal and molecular genetics. With 120 years of expertise and innovation in the service of clinical pathology, Eurofins Biomnis forms the core of the Clinical Diagnostics division of the Eurofins Group in Europe and is actively expanding in worldwide markets. [www.eurofins-biomnis.com](http://www.eurofins-biomnis.com)

